[Latest] Global PARP Inhibitors Market Size/Share Worth USD 23.5 Billion by 2032 at a 12.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) Austin, TX, USA, March 28, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “PARP Inhibitors Market Size, Trends and Insights By Type (Olaparib, Rucaparib,...

Global PARP Inhibitors Cancer Therapy Market Outlook 2022-2028: PARP Inhibitors have Proved to be a Commercial Success in the Modern Cancer Therapeutic Segment Dublin, June 08, 2022 (GLOBE NEWSWIRE) -- The "Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's...

Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer CALGARY, Alberta, June 27, 2019 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a wholly-owned subsidiary of Zenith Capital Corp., announced today that it has dosed the...

Zenith Epigenetics Announces Clinical Trial Collaboration with Pfizer Collaboration to evaluate ZEN-3694 in combination with Talazoparib in TNBC patients; Phase 1b/2 trial expected to initiate 1Q 2019 CALGARY, Alberta, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Zenith...